Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$3.05M$3.05Mderived−6.0% vs Q4 2018 Net Income-$18.75M-$18.75MderivedN/M vs Q4 2018 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$289,347N/M Operating Incomederived-$18,675,473N/M Operating Cash Flowderived-$795,366N/M Free Cash Flowderived-$845,630N/M Margins · derivedGross margin9.5%+14.8 pt vs Q4 2018
Operating margin-612.6%−381.0 pt vs Q4 2018
Net margin-614.9%−380.8 pt vs Q4 2018
ended Dec 31, 2019 · filed Mar 30, 2020 · 90 d after period end